I. Introduction
The literature on allergic rhinitis (AR) continues to grow, yet there is substantial variation in the type and quality of AR publications. As the allergy practitioner, researcher, or academician evaluates the literature, it is critical to understand the strength and quality of the evidence to allow for appropriate translation to daily clinical care in AR. The International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis (ICAR:AR) 1 was developed to summarize and critically review the best external evidence in the realm of AR. This includes broad categories of epidemiology, risk factors, diagnosis, management, and associated conditions/comorbidities related to AR. Over 100 individual AR topics were developed through a process of primary authorship, iterative reviews by additional authors, and close editorial evaluation. ICAR:AR follows previously developed methodology that has produced numerous evidence-based reviews with recommendations in the International Forum of Allergy and Rhinology, as well as the 2016 ICAR: Rhinosinusitis document. 2 Using this established methodology, ICAR:AR provides a strong and critical review of the existing AR literature. Recommendations for AR diagnosis and treatment modalities contained in the ICAR:AR document rely directly on the best external evidence, while also considering benefit, harm, and cost considerations for determination of each recommendation level. ICAR:AR is not a standard literature review or an expert panel report. Systematic literature searches, structured grading of evidence, initial anonymous review of each section followed by achievement of consensus, and close critique of the manuscript by a panel of editors during the ICAR:AR process minimizes reliance on expert opinion and other potential biases. ICAR:AR, however, is not a manual or flowchart for the treatment of AR patients. ICAR:AR summarizes the best available AR evidence and, when appropriate, develops recommendations from this evidence. This is similar to the systematic literature review performed for a clinical practice guideline. However, it should also be noted that ICAR:AR is not a clinical practice guideline, because certain steps of clinical practice guideline development (ie, medical specialty society and patient advocate review) were not utilized in the ICAR:AR process.
Although some topics in the ICAR:AR document have very strong evidence, the evidence in other topic areas is weak. Some of our routine practices in the evaluation and management of the AR patient are based on weak external evidence. Through the process of developing the ICAR:AR document, we have identified several knowledge gaps in the understanding of epidemiology, risk factors, diagnosis, and treatment of AR. We anticipate that the summary of the evidence in AR will help to direct additional research efforts as we strive to improve patient outcomes.
This Executive Summary is a synopsis of the full ICAR:AR document. The summaries of the evidence grades and recommendation levels are provided in this Executive Summary, but the description of the literature that supports these evidence grades and recommendation levels is found in the full ICAR:AR document. The reader is directed to the full ICAR:AR document for detailed information.
II. Methods
Each of 103 AR topics was assigned to 1 of 72 content experts worldwide. Some of the topics, such as those providing background or definitions, were assigned as literature reviews without evidence grades. Topics that were not appropriate for clinical recommendations were assigned as evidence-based reviews without recommendations (EBRs). Topics that had sufficient evidence to inform clinical recommendations were assigned as evidence-based reviews with recommendations (EBRRs). The methodology for EBR and EBRR topic development was based on the work of Rudmik and Smith. 3 Briefly, for each topic, specific instructions were given to perform a systematic review for the topic literature using the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) standardized guidelines. 4 Ovid MEDLINE R (1947 to September 2016), EMBASE (1974 to September 2016), and Cochrane Review databases were included. Published systematic reviews, meta-analyses, and randomized, controlled trials (RCTs) were highlighted during the search as providing the highest levels of evidence. Included studies in EBR and EBRR topic sections are presented in a standardized table format, with the level of evidence delineated. At the completion of the systematic review and research quality evaluation for each clinical topic, an aggregate grade of evidence was produced for the topic based on the guidelines from the American Academy of Pediatrics Steering Committee on Quality Improvement and Management (AAP SCQIM). 5 For EBRR sections, an evidence-based recommendation was produced. This recommendation considered the aggregate grade of evidence, as well as the balance of benefit, harm, and costs. Please refer to the full ICAR:AR document Methods section and Table II .A-2 for the specifics of recommendation level determination.
Following initial topic development, each section then underwent a 2-stage online iterative review process using 2 independent reviewers. This iterative review process evaluated the completeness of the included literature and assessed the appropriateness of EBRR recommendations. Following topic development and 2 iterative reviews, the principal editor (S.K.W.) compiled all topics into 1 ICAR:AR statement. A panel of 6 to 8 authors further reviewed each large ICAR:AR portion (ie, Evaluation and Diagnosis, Pharmacotherapy, Immunotherapy, etc) for consistency and understanding. Finally, the draft ICAR:AR was circulated to all authors for consensus.
Although the ICAR:AR document aims to be systematic and thorough in its methods, there are some limitations. First, each topic author individually performed the literature search for his/her assigned topic, which introduces some variability despite detailed literature search instructions. Second, this document does not present every study published on every topic. For certain topics, the literature is extensive and only high-quality studies or systematic reviews are listed. If the aggregate evidence on a topic reached a high evidence grade with only high-level studies, an exhaustive list of lower level studies (or all studies ever performed) is not provided.
III. Results
The ICAR:AR document addresses several significant areas, including:
1. Definitions, classification, and differential diagnosis of AR. 2. A synopsis of the pathophysiology and mechanisms of AR. 
III.A. Results-definitions, classification, and differential diagnosis of allergic rhinitis
In the ICAR:AR document, AR is defined as an immunoglobulin E (IgE)-mediated inflammatory nasal condition resulting from allergen introduction in a sensitized individual, which is based on the Allergic Rhinitis and its Impact on Asthma (ARIA) document. 6 Classification of AR typically includes seasonal vs perennial and intermittent vs persistent. Sensitization to an allergen is indicated by a positive reaction on allergy skin test or antigen-specific IgE test, whereas clinical allergy is evidenced by active symptoms upon allergen exposure in a sensitized individual. Not all sensitized individuals exhibit clinical allergy. The differential diagnosis of AR is rather extensive and includes numerous inflammatory conditions of the sinonasal region. Of note, the section on AR differential diagnosis is specific to various etiologies of rhinitis. Other entities that may enter into the differential diagnosis of AR, such as structural sinonasal conditions (ie, deviated septum), tumors, and cerebrospinal fluid leak, are not discussed (Table III. 
III.C. Results-epidemiology of allergic rhinitis
The epidemiology of AR has been quantified by various means in adults and children. Our current understanding of the prevalence of AR primarily results from large epidemiologic survey studies. However, it should be noted that surveys differ in terms of disease definitions, geography, and seasonality of the area surveyed. These issues can introduce variability into prevalence estimates drawn from survey data. A discussion of the prevalence of AR in adults, incidence and prevalence of AR in children, and geographic variation of AR is provided in the ICAR:AR document.
III.D. Results-risk factors for allergic rhinitis
The authors of ICAR:AR reviewed several potential risk factors for the development of AR, as well as some proposed protective factors against the development of AR. The summary of these findings is shown in Tables III.D.1. and III.D.2. The ICAR:AR document reviews each of these factors in detail.
III.E. Results-disease burden
The ICAR:AR authors reviewed the disease burden of AR regarding its effect on quality of life (QoL) and sleep at the level of the individual. The summary of these findings is shown in Table III .E. The societal impact of AR was also considered.
r QoL: Based on systematic reviews, it has been concluded that AR patients suffer from significantly decreased general and disease-specific QoL due to the impact of physical and mental health. Treatment of AR leads to QoL improvements. r Societal burden: The societal burden of AR can be quantified in direct costs, indirect costs, lost work/school days, and other measures. By any account, as one of the most common chronic diseases in adults and children, AR has a substantial impact on society. These issues are discussed in further detail in the ICAR:AR document.
III.F. Results-evaluation and diagnosis
During patient evaluation, the suspicion of AR is based on clinical history and often supported by physical examination. Various methods of objective testing may also be used in the diagnosis of AR. The ICAR:AR authors reviewed numerous modalities for the diagnosis of AR. The summary of these findings is shown in Table III .F. This section summarizes the recommendations for each method of evaluation and diagnosis of AR that was reviewed in the ICAR:AR document.
r Clinical examination (history and physical): Nasal cytology 4 C -Nasal cytology is an investigational tool, rather than diagnostic.
Nasal histology 11 B -Nasal histology is used for research on the pathophysiology of AR, but is not routinely used in clinical practice for the diagnosis of AR.
• Intervention: Nasal endoscopy may increase diagnostic sensitivity among children and adults with AR and may aid in ruling out other causes for nasal symptoms.
r Radiology:
• Aggregate Grade of Evidence: Not applicable.
• Benefit: None appreciated.
• Harm: Unnecessary radiation exposure with concern for tumor development. • Cost: High equipment and processing costs.
• Benefits-Harm Assessment: Preponderance of harm over benefit. • Value Judgments: Long-term risks of unnecessary ionizing radiation exposure outweigh potential benefit. • Policy Level: Recommend against.
• Intervention: Routine imaging is not recommended in the evaluation of suspected AR, but may be considered to rule-in/out other sinonasal conditions.
r Use of validated survey instruments:
• Aggregate Grade of Evidence: A (Level 1a: 2 studies; Level 1b: 4 studies; Level 2b: 4 studies). Note: multiple additional studies reviewed, but Grade A evidence was reached with these 10 studies, so an extensive listing of all studies employing validated survey instruments is not provided in the ICAR:AR document. • Intervention: SPT is recommended for evaluation of allergen sensitivities in appropriately selected patients. Regular use of the same SPT device will allow clinicians to familiarize themselves with it and interpretation of results may therefore be more consistent. The use of standardized allergen extracts can further improve consistency of interpretation.
r Skin intradermal testing: r Serum total IgE (tIgE):
• Aggregate Grade of Evidence: C (Level 2b: 5 studies; Level 3b: 10 studies). • Benefit: Possibility to suspect allergy in a wide screening. r Nasal cytology:
• Aggregate Grade of Evidence: C (Level 3b: 3 studies; Level 4: 1 study). Nasal cytology is largely an investigational tool.
r Nasal histology:
• Aggregate Grade of Evidence: B (Level 1b: 8 studies; Level 3b: 3 studies). Nasal histology is used for research on the pathophysiology of AR, but is not used routinely in clinical practice for the diagnosis of AR.
III.G. Results-management
Various management options for the treatment of AR were reviewed by the ICAR:AR authors. These are broken down into 4 broad topic areas-avoidance measures, pharmacotherapy, surgical treatment, and AIT.
III.G.1. Results-management: avoidance measures
Avoidance measures and environmental controls may include physical and chemical means to reduce allergen load. These methods have been advocated for the reduction of allergy symptoms, based on the principle that decreased allergen exposure may result in decreased symptomatology. Avoidance measures and environmental control methods were reviewed for house dust mite (HDM), cockroach, pet, and pollen/occupational allergens. The summary of these findings is shown in r Cockroach: In a substantial number of RCTs that evaluated the efficacy of specific environmental control measures to eliminate the number of cockroaches and reduce cockroach allergen level, respiratory health outcomes were rarely measured. Most studies did not include r Pets: Pet removal is a commonly cited strategy without high-quality outcomes evaluation. Therefore, pet avoidance and environmental controls represent options for the treatment of AR. Recommendations are as follows:
• Aggregate Grade of Evidence: B (Level 1b: 1 study; Level 2b: 2 studies). 
III.G.2. Results-management: pharmacotherapy
Medications are often used to control allergic symptoms. The ICAR:AR authors reviewed numerous medication options for their use in the treatment of AR. The summary of these findings is shown in • Cost: Low.
• Benefits-Harm Assessment: The risks of using oral corticosteroids outweigh the benefits when compared with similar symptom improvement with the use of INCSs. • Value Judgments: In the presence of effective symptom control using INCS, the risk of adverse effects from using oral corticosteroids for AR appears to outweigh the potential benefits. • Policy Level: Recommendation against the routine use of oral corticosteroids for AR. • Intervention: Although not recommended for routine use in AR, certain clinical scenarios warrant the use of short courses of systemic corticosteroids after a discussion of the risks and benefits with the patient. This may include patients with significant nasal obstruction that would preclude penetration of intranasal agents (INCSs or antihistamines). In these cases, a short course of systemic oral corticosteroids could improve congestion and facilitate access and efficacy of the topical agents.
r Injectable corticosteroids:
• • Harm: INCS have known undesirable local adverse effects, such as epistaxis with some increased frequency compared with placebo in prolonged administration studies. There are no apparent negative effects on the hypothalamic-pituitary axis. There may be some negative effects on short-term growth in children, but it is unclear whether these effects translate into long-term growth suppression. r Combination oral antihistamine and oral decongestant:
• Aggregate Grade of Evidence: A (Level 1b: 21 studies). • Benefit: Improved control of nasal congestion with combination of oral antihistamines and oral decongestants. • Harm: Oral decongestants can cause significant adverse effects, particularly in patients with hypertension, cardiovascular disease, or benign prostatic hypertrophy. In addition, these medications should not be used in children under 4 years of age or in pregnant patients. This should be weighed against the potential benefits prior to prescribing.
• Cost: Low.
• Benefits-Harm Assessment: Harm likely outweighs benefit when used on a routine basis. • Value Judgments: Combination therapy of oral antihistamines and oral decongestants can be helpful for relief of an acute exacerbation of AR, especially nasal symptoms, when exposed to triggers. Caution should be exercised regarding longterm use, given the possibility of significant adverse effects. • Policy Level: Option, particularly for acute exacerbations of nasal congestion. • Intervention: Combination therapy with oral antihistamine and oral decongestant can provide effective reduction of nasal congestion symptoms in patients with AR; however, there is recommendation against long-term use given the significant sideeffect profile of oral decongestants.
r Combination oral antihistamine and intranasal corticosteroid:
• Aggregate Grade of Evidence: B (Level 1b: 5 studies). r Combination oral antihistamine and leukotriene receptor antagonist:
• Aggregate Grade of Evidence: A (Level 1a: 1 study; Level 1b: 11 studies; Level 2b: 1 study). • Benefit: Inconsistent evidence that combination LTRA and oral antihistamine were superior in symptom reduction and QoL improvement than either agent as monotherapy. Combination therapy is inferior in symptom reduction compared with INCS alone. • Harm: No significant safety-related adverse events from combination therapy. • Costs: Generic montelukast was more expensive than either generic loratadine or cetirizine on a per-dose basis, according to weekly data provided by the Centers for Medicare and Medicaid Services. r Combination intranasal corticosteroid and intranasal antihistamine:
• Aggregate Grade of Evidence: A (Level 1b: 9 studies; Level 2b: 1 study; Level 2c: 2 studies). • Benefit: Rapid onset, more effective for relief of multiple symptoms than either INCS or intranasal antihistamine alone. • Harm: Patient intolerance, especially due to taste.
• Costs: Moderate financial burden; average wholesale price of $202 USD per 23-gram bottle (1-month supply when used as labeled). • Benefits-Harm Assessment: Preponderance of benefit over harm. Combination therapy with intranasal antihistamine and INCS is consistently more effective than placebo; there is low risk of nonserious adverse effects. • Value Judgments: Despite Level 1 evidence demonstrating that combination spray therapy (INCS plus intranasal antihistamine) is more effective than monotherapy and placebo, the increased financial cost and need for prescription limit the value of combination therapy as a routine first-line treatment for AR. • Policy Level: Strong recommendation for the treatment of AR when monotherapy fails to control symptoms. r Acupuncture:
• Aggregate Grade of Evidence: B (Level 1a: 2 studies; Level 2b: 13 studies). • Benefit: Unclear, as 1 meta-analysis showed no overall effects of acupuncture on AR symptoms or need for rescue medications, and a second metaanalysis showed an effect of acupuncture on symptoms, QoL, and need for rescue medications. • Harm: Needle sticks associated with minor adverse events, including skin irritation, pruritis, erythema, subcutaneous hemorrhage, infection, and headache. Need for multiple treatments and possible ongoing treatment to maintain any benefit gained. • Cost: Cost of acupuncture treatment with multiple treatments required. • Benefits-Harm Assessment: Balance of benefit and harm. • Value Judgments: The authors determined that the evidence was inconclusive but that acupuncture could be appropriate for some patients to consider as an adjunct therapy. • Policy Level: Option.
• Intervention: In patients who wish to avoid medications, acupuncture may be suggested as a possible therapeutic adjunct.
r Honey:
• Aggregate Grade of Evidence: B (Level 1b: 2 studies; Level 2b: 1 study). • Benefit: Unclear, as studies have shown differing results. Honey may be able to modulate symptoms and decrease need for antihistamines. • Harm: Some patients stopped treatment because they could not tolerate the level of sweetness. Some patients could have an allergic reaction to honey intake, and, in rare instances, anaphylaxis. Use of this therapy in prediabetics and diabetics would likely need to be avoided out of concern for elevated blood glucose levels. r Herbal therapies:
• Aggregate Grade of Evidence: Uncertain. • Benefit: Unclear, but some herbs may be able to provide symptomatic relief.
• Harm: Some herbs are associated with mild side effects. Also, the safety and quality of standardization of herbal medications is unclear. • Cost: Cost of herbal supplements is variable.
• Benefits-Harm Assessment: Unknown.
• Value Judgments: The authors determined that there is a lack of sufficient evidence to recommend the use of herbal supplements in AR. • Aggregate Grade of Evidence: C (Level 1a: 1 study;
Level 1b: 1 study; 
III.G.4. Results-management: allergen immunotherapy
AIT is one of the management options for AR. Through scheduled administration of allergen extracts at effective doses, AIT aims to effect a sustained immunologic change, resulting in control of allergy symptoms and reduction in allergy medication use. A description of allergen extract units, potency, and standardized vs nonstandardized allergen extracts is found in the ICAR:AR document. This information is necessary in developing a meaningful understanding of AIT. In additional to traditional allergen extracts, which are created by collecting raw material from a plant, mold, or animal and then using a solution to extract proteins from the source, modified allergen extracts have also been developed and studied in AIT. These modified allergen extracts aim to decrease adverse events associated with AIT, limit extract production costs, or increase consistency between batches. The laboratory production of allergens allows for modification of extracts and epitope structures that aim to enhance immunogenicity while decreasing the risk of adverse reactions. Modified allergen extracts include recombinant allergens, peptide constructs, allergoids and polymerized allergens, and adjuvant constructs, each of which is discussed in the ICAR:AR document.
Various AIT methods and their efficacy in AR were reviewed. The summary of these findings is shown in Table  III .G.4.
r Subcutaneous immunotherapy (SCIT): High-level evidence demonstrates that SCIT is effective for the treatment of AR. There are many nuances to providing SCIT for the treatment of AR, including patient selection, knowledge of contraindications, selection of allergen extracts, dosing, monosensitized vs polysensitized patients, and use of single vs multiple allergen immunotherapy, along with various mixing and administration options and other considerations. The ICAR:AR document should be consulted for a more thorough discussion of these issues. Recommendations are as follows:
• Aggregate Grade of Evidence: A (Level 1a: 3 recent studies listed; Level 1b: 5 recent studies listed). Of note, due to the large body of literature supporting SCIT as a treatment for AR, only recent systematic reviews and select double-blind, placebo-controlled RCTs were reviewed. • Benefit: Improvement in symptoms and decreased need for rescue medication. There is a decreased likelihood of progression from AR to bronchial asthma. Persistent benefit for years after completion of 3 to 5 years of SCIT. • Harm: Inconvenience of multiple visits to a medical facility to receive injections. Potential for systemic reactions, including anaphylaxis. • Cost: Cost for preparation of allergen extract for treatment, as well as costs associated with visits to medical facilities to receive injections. • Benefits-Harm Assessment: Benefit greater than harm for patients who cannot obtain adequate relief with symptomatic treatment and whose symptoms extend more than a few weeks each year. • Value Judgments: Patients who can obtain adequate relief of symptoms with medication must decide if the short-term increased cost and inconvenience of SCIT is compensated for by the long-term, persisting clinical benefit and relief from need to take medication. Pharmacoeconomic studies suggest that, in the long term, SCIT is cost-effective compared with symptomatic therapy. • Policy Level: Strong recommendation for SCIT in patients unable to obtain adequate relief with symptomatic therapy. • Intervention: SCIT should be recommended to AR patients who cannot obtain adequate relief from symptomatic medication for significant periods of time each year and to those who would benefit from its secondary disease-modifying effects (prevention of bronchial asthma and new sensitization), particularly children and adolescents.
r Sublingual immunotherapy (SLIT): The literature on SLIT for AR is strong, with several good meta-analyses and systematic reviews published over the past decade. Like SCIT, there are several aspects of treatment that need to be considered. These include, but are not limited to, treatment of adults vs children, efficacy and safety of SLIT vs SCIT, cost-effectiveness, specific choice of allergen, and SLIT treatment method (ie, aqueous drops vs tablets). The ICAR:AR document should be consulted for a more thorough discussion of these issues. Recommendations are as follows:
• Aggregate Grade of Evidence: A (Level 1a: 10 studies; Level 1b: 3 studies; Level 2a: 11 studies; Level 3a: 1 study). • Benefit: SLIT improved patient symptom scores, even as add-on treatment on top of rescue medication. SLIT reduced medication use. The effect of SLIT lasted for at least 2 years after a 3-year course of high-dose therapy. Benefit is generally higher than with single-drug pharmacotherapy, but possibly somewhat less than with SCIT. • Harm: Minimal harm with very frequent, but mild, local adverse events. Systemic adverse events are very rare. SLIT seems to be safer than SCIT. r Alternative forms of AIT: Oral/gastrointestinal, nasal, and inhaled (intrabronchial) AIT represent alternate options for the treatment of AR, with primarily historic significance. Oral/gastrointestinal immunotherapy has not shown significant benefit for treatment of aeroallergen sensitivity. Local nasal immunotherapy demonstrates efficacy, but local adverse reactions limit patient compliance. High-quality studies of inhaled/intrabronchial immunotherapy for the treatment of AR have not been performed. Oral mucosal immunotherapy is a new, alternative form of AIT different from SLIT and oral/gastrointestinal strategies, in which a glycerin-based toothpaste vehicle introduces antigen to high-density antigen-processing oral Langerhans cells in the oral vestibular and buccal mucosa. Additional study is needed to define the role of oral mucosal immunotherapy in the treatment of AR.
r Combination omalizumab and subcutaneous immunotherapy: Potential benefits of combination therapy include decreased incidence of AIT-associated systemic allergic reactions and improved control of AR symptoms. Four RCTs have evaluated this combination, and 2 additional iterative analyses of a parent RCTs have been performed. Recommendations are as follows:
• Aggregate Grade of Evidence: B (Level 1b: 4 studies, plus 2 additional iterative analyses of a parent study). • Benefit: Improved safety of accelerated cluster and rush AIT protocols, with decreased symptom and rescue medication scores among a carefully selected population. • Harm: Financial cost and risk of anaphylactic reactions. • Cost: Moderate to high.
• Benefits-Harm Assessment: Preponderance of benefit over harm. • Value Judgments: Combination therapy increases the safety of AIT, with decreased systemic reactions following cluster and rush protocols. Associated treatment costs and likelihood of systemic reactions must be considered, with greater consideration for omalizumab pretreatment prior to higher-risk AIT protocols. Although 2 high-quality RCTs have demonstrated improved symptom control with combination therapy over AIT or omalizumab alone, not all patients will require this approach. Rather, an individualized approach to patient management must be considered, with evaluation of alternative causes for persistent symptoms, such as unidentified allergen sensitivity. The current evidence does not support the utilization of combination therapy for all patients failing to benefit from AIT alone. • Policy Level: Option, based on current evidence.
However, it is important to note that omalizumab is not currently approved by the FDA for the treatment of AR. • Intervention: Omalizumab may be offered as a premedication before induction of cluster or rush AIT protocols. Combination therapy is an option for carefully selected patients with persistent symptomatic AR following AIT. An individualized approach to patient management must be considered. In addition, as omalizumab is not currently approved by the FDA for AR treatment, in the United AD 20 C There is evidence for an association between AR and AD.
Food allergy and PFAS 12 B
There is evidence for a link between pollen allergy and PFAS.
Adenoid hypertrophy 11 C Data inconclusive.
Otologic conditions: ETD 7 C There is a causal role for AR in some cases of ETD.
Otologic conditions: otitis media 16 C Relationship between AR and OTE is unclear.
Otologic conditions: Meniere's disease 8 C Evidence for an association is of low grade, with substantial defects in study design.
Cough 9 C Low level evidence for an association between AR and cough.
Laryngeal disease 18 C There is some evidence for an association between AR and laryngeal disease. asthma that is uncontrolled despite maximal conventional interventions. However, given the significantly increased cost associated with omalizumab, the value of this therapy is likely greatest for patients with severe asthma and symptoms that persist despite usual therapies.
r Policy Level: Omalizumab is recommended for those patients with clear IgE-mediated allergic asthma with coexistent AR who fail conventional therapy. The significant additional cost of this therapy should be considered in its evaluation. AIT: Evidence for SCIT and SLIT for asthma in the context of comorbid AR was reviewed. Recommendations are as follows:
r Aggregate Grade of Evidence: A (Level 1a: 2 studies; Level 1b: 4 studies; Level 2b: 1 study).
r Benefit: AIT (both SCIT and SLIT) has demonstrated benefit in concomitant AR and asthma, with decreased symptoms, rescue medication use, and bronchial hyperresponsiveness, as well as reduced development of asthma in patients with AR only.
r Harm: Local-site reactions are common and there is potential for anaphylactic events with any form of AIT.
r Cost: Increased cost compared with standard therapy for AR and asthma, although the potential to treat the underlying disease process and prevent progression of disease could reduce long-term costs.
r Benefits-Harm Assessment: Significant evidence to support the use of AIT for patients with AR and asthma, as well as the potential utility of AIT for preventing progression of allergic disease from AR to the development of allergic asthma. Harm events are generally limited to minor local reactions, but there is Evidence: C (Level 2b: 8 studies; Level 3a: 1 study; Level 3b: 4 studies; Level 4: 5 studies).
r Eosinophilic esophagitis (EoE): Studies examining the prevalence of clinician-diagnosed AR and aeroallergen sensitization in patients with EoE support an association between these entities. There are limited observational data, however, suggesting a potential association between aeroallergens and EoE pathogenesis. Aggregate Grade of Evidence: C (Level 3a: 1 study; Level 4: 12 studies).
r Sleep disturbance and obstructive sleep apnea: Nasal obstruction due to AR may substantially affect sleep, and sleep disturbance in AR patients is shown to affect QoL, work performance, and productivity. A correlation between AR severity and sleep disturbance has been demonstrated. Aggregate Grade of Evidence: B (Level 1b: 5 studies; Level 2b: 1 study; Level 2c: 5 studies; Level 3b: 7 studies; Level 4: 2 studies).
IV. Discussion
This Executive Summary has reviewed several key findings of the ICAR:AR document. Although certain areas demonstrate strong evidence to support AR diagnosis and treatment decisions, other areas show substantially weaker evidence and would benefit from additional study. For example, large RCTs, systematic reviews, and meta-analyses have demonstrated the benefit of INCSs and nonsedating second-generation antihistamines in the treatment of AR (Aggregate Grade of Evidence A). In contrast, evidence for the association of most studied risk factors (ie, genetics, inutero allergen exposure, pollution, socioeconomic status) in the development of AR is weaker, with an Aggregate Grade of Evidence C.
Even within specific topic areas, the evidence may be varied. For example, the overall evidence for the use of SLIT in the treatment of AR is quite strong, with numerous systematic reviews and meta-analyses of RCTs. However, when evaluating the evidence for SLIT in AR in specific subgroups or more directed questions (ie, cost-effectiveness, long-term effectiveness, epithelial antigens, fungal antigens), the evidence is weaker.
Like the 2016 ICAR: Rhinosinusitis document, several areas were identified through the ICAR:AR process where relatively low levels of evidence guide our everyday clinical care of the AR patient. One example is the use of blended skin testing techniques, consisting of SPT followed by selected intradermal tests, often based on a predetermined algorithm. Although the Aggregate Grades of Evidence for SPT alone is B and skin intradermal testing alone is also B, studies to support the benefit of blended skin prick and intradermal techniques are rare, with an Aggregate Grade of Evidence of D. As many clinicians use this technique in practice, additional study is warranted. Another example is provided by the evidence supporting/refuting the association between AR and rhinosinusitis. Many practitioners commonly associate AR with ARS, RARS, or CRS, yet the evidence for this association is poor, as demonstrated by Aggregate Grades of Evidence C or D. The studies for ARS and RARS association with AR are few, but they have demonstrated a potential association between AR and ARS (Grade C evidence). The studies for RARS and CRS are highly conflicting and do not currently support an association (Grade D evidence). One consideration in analyzing this evidence, especially for the patients with CRSwNP, is the classic phenotypic definition of CRS (ie, with and without nasal polyposis). As our understanding of CRS advances, and we lean more toward endotype classifications of this disease, in addition to separating nasal polyp groups (ie, aspirin-exacerbated, allergic fungal rhinosinusitis, cystic fibrosis), we will likely find that AR has a greater association with certain types of CRS than the much broader categories of CRSsNP and CRSwNP.
The examples above highlight some of the benefits of the ICAR:AR document, as it has demonstrated the areas where our AR evidence is solid while also identifying knowledge gaps. As we acknowledge these gaps, we encourage further research and improvement of our understanding of AR from a pathophysiologic, diagnostic, and treatment perspective.
